FFFranck Festy

Franck Festy

*This is an algorithmically generated author record based on publicly available information.

Franck Festy has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Combined therapy for critical limb ischaemia: Biomimetic PLGA microcarriers potentiates the pro-angiogenic effect of adipose tissue stromal vascular fraction cells

    by Laurence Hoareau, Florian Fouchet, Cynthia Planesse, Sophie Mirbeau, Laurence Sindji, Emmanuel Delay, Régis Roche, Claudia N. Montero-Menei, Franck Festy

    We propose a regenerative solution in the treatment of critical limb ischemia. Poly‐lactic/glycolic acid (PLGA) microcarriers were prepared and coated with laminin to be sterilized through γ‐irradiation of 25 kGy at low temperature. Stromal vascular fraction (SVF) cells were extracted through enzymatic digestion of adipose tissue. Streptozotocin‐induced diabetic mice underwent arteriotomy and received an administration of SVF cells combined or not with biomimetic microcarriers. Functional evaluation of the ischemic limb was then reported and tissue reperfusion was evaluated through fluorescence molecular tomography (FMT). Microcarriers were stable and functional after γ‐irradiation until at least 12 months storage. Mice which received an injection of SVF cells in the ischemic limb have 22 % of supplementary blood supply within this limb 7 days after surgery compared to vehicle, whereas no difference was observed at day 14. With the combined therapy, the improvement of blood flow is significantly higher compared to vehicle, of about 31 % at day 7 and of about 11 % at day 14. Injection of SVF cells induces a significant 27 % decrease of necrosis compared to vehicle. This effect is more important when SVF cells were mixed with biomimetic microcarriers: ‐ 37% compared to control. Although SVF cells injection leads to a non‐significant 22 % proprioception recovery, the combined therapy induces a significant recovery of about 27 % compared to vehicle. We show that the combination of SVF cells from adipose tissue with laminin‐coated PLGA microcarriers is efficient for CLI therapy in a diabetic mouse model.